Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 9Unknown 4Recruiting 4Withdrawn 3Terminated 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 41Pancreatic Neoplasms 17Breast Neoplasms 17Esophageal Neoplasms 14Neoplasms 13Stomach Neoplasms 12Lung Neoplasms 12Triple Negative Breast Neoplasms 11Rectal Neoplasms 11Neoplasm Metastasis 11Esophageal Squamous Cell Carcinoma 11Uterine Cervical Neoplasms 10Colorectal Neoplasms 10Small Cell Lung Carcinoma 9Ovarian Neoplasms 9Head and Neck Neoplasms 7Nasopharyngeal Carcinoma 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Leukemia, Myeloid, Acute 5Endometrial Neoplasms 5Colonic Neoplasms 5Recurrence 4NSCLC 4Mouth Neoplasms 4Lymphoma 3Glioma 3Cholangiocarcinoma 3Adenocarcinoma Of Esophagus 3Urinary Bladder Neoplasms 2

Interventions

Cyclophosphamide 21venetoclax 18pembrolizumab 16Dexamethasone 16fludarabine 14Cytarabine 13Gemcitabine 9pomalidomide 8Rituximab 8Carboplatin 8Azacitidine 8glofitamab 7fludarabine phosphate 7Lenalidomide 7Immunotherapy, Adoptive 7selinexor 6Paclitaxel 6Injections 6Granulocyte Colony-Stimulating Factor 6Cisplatin 6daratumumab 5Temozolomide 5Oxaliplatin 5Bevacizumab 5zanubrutinib 4ruxolitinib 4Surgical Procedures, Operative 4Nivolumab 4Drug Therapy 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Recurrence × Drug Therapy × Clear all
NCT02961101 2026-01-22

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Chinese PLA General Hospital

Phase 1/2 Recruiting
250 enrolled

Neoplasms, Recurrence

NCT06090864 2025-10-20

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
31 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT07022002 2025-08-03

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 2 Recruiting
340 enrolled

Neoplasms, Recurrence

NCT06670911 2025-02-24

ACCESS-I

Instituto Nacional de Cancer, Brazil

Phase 2 Recruiting
44 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡